Pronto disponible para inscripción
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.
AMG 355_20220028 (Solid Tumors) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called AMG 355 (the study drug) is a safe and effective option for people who have a solid tumor form of cancer that is metastatic (spread to surrounding tissues in the body). We want to know how well the study drug works on its own or in combination with an approved cancer drug called pembrolizumab.
What is the Condition Being Studied?
Metastatic, Advanced Solid Tumor Cancers
Who Can Participate in the Study?
Adults ages 18+ who have one of the following forms of cancer that has come back after treatment or did not respond to standard therapy:
- cáncer de pulmón de células no pequeñas
- cáncer colorrectal
- Cáncer gástrico
- Melanoma
For more information, contact the study team at ryan.woelfel@duke.edu.
Grupo etario
Adultos
What is Involved?
Si decide unirse a este estudio, recibirá una asignación aleatoria (como lanzar una moneda al aire) a 1 de 2 grupos:
- Group A: If you are in this group, you will take only the study drug while you are in the study.
- Group B: If you are in this group, you will take the study drug in combination with pembrolizumab while you are in the study.
Study Details
Full Title
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Principal Investigator
Christopher Hoimes
Protocol Number
IRB:
PRO00116617
NCT:
NCT06131398
Phase
Fase I
ClinicalTrials.gov
View on ClinicalTrials.gov
Estado de inscripción
Pronto disponible para inscripción